Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 3 (March)

1. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome.
   Obstet Gynecol, 105(3): 569-74. [Abstract] [Full-text]
2. Ovarian malignancy in breast cancer patients with an adnexal mass.
   Obstet Gynecol, 105(3): 507-13. [Abstract] [Full-text]
3. Early detection of breast and ovarian cancer in families with BRCA mutations.
   Eur J Cancer, 41(4): 549-54. [Abstract] [Full-text]
4. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
   Eur J Cancer, 41(4): 539-48. [Abstract] [Full-text]
5. Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon.
   Jpn J Clin Oncol, 35(3): 154-7. [Abstract] [Full-text]
6. Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling.
   Oncogene, 24(10): 1774-87. [Abstract] [Full-text]
7. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival.
   Am J Obstet Gynecol, 192(3): 819-25. [Abstract] [Full-text]
8. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer.
   Am J Obstet Gynecol, 192(3): 807-12. [Abstract] [Full-text]
9. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases.
   Reprod Toxicol, 19(4): 557-61. [Abstract] [Full-text]
10. Aromatase expression in ovarian epithelial cancers.
    J Steroid Biochem Mol Biol, 93(1): 15-24. [Abstract] [Full-text]
11. Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma.
    Arch Gynecol Obstet, 271(2): 182-3. [Abstract] [Full-text]
12. Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas.
    Arch Gynecol Obstet, 271(2): 104-8. [Abstract] [Full-text]
13. Pure nongestational choriocarcinoma of ovary.
    Arch Gynecol Obstet, 271(2): 176-7. [Abstract] [Full-text]
14. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
    Arch Gynecol Obstet, 271(2): 123-6. [Abstract] [Full-text]
15. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer.
    J Zhejiang Univ Sci B, 6(4): 227-31. [Abstract] [Full-text]
16. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
    Hum Pathol, 36(2): 195-201. [Abstract] [Full-text]
17. Racial differences in the familial aggregation of breast cancer and other female cancers.
    Breast Cancer Res Treat, 89(3): 227-35. [Abstract] [Full-text]
18. Ovarian choriocarcinoma in a rhesus monkey associated with elevated serum chorionic gonadotropin levels.
    Vet Pathol, 42(2): 226-9. [Abstract] [Full-text]
19. Ovarian epithelioid trophoblastic tumor in a cynomolgus monkey.
    Vet Pathol, 42(2): 223-6. [Abstract] [Full-text]
20. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
    Cancer Res, 65(5): 1994-2000. [Abstract] [Full-text]
21. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo.
    Clin Cancer Res, 11(5): 1798-808. [Abstract] [Full-text]
22. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer.
    Vaccine, 23(17): 2374-8. [Abstract] [Full-text]
23. Ovarian cancer patients' psychological distress: the role of physical impairment, perceived unsupportive family and friend behaviors, perceived control, and self-esteem.
    Health Psychol, 24(2): 143-52. [Abstract] [Full-text]
24. Ascitic complement system in ovarian cancer.
    Br J Cancer, 92(5): 895-905. [Abstract] [Full-text]
25. Bilateral ovarian leiomyomas: CT and MRI features.
    Abdom Imaging, 30(1): 117-9. [Abstract] [Full-text]
26. Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation.
    J Clin Endocrinol Metab, 90(3): 1670-7. [Abstract] [Full-text]
27. Expression of growth hormone secretagogue receptor type 1a, the functional ghrelin receptor, in human ovarian surface epithelium, mullerian duct derivatives, and ovarian tumors.
    J Clin Endocrinol Metab, 90(3): 1798-804. [Abstract] [Full-text]
28. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Mod Pathol, 18: S61-79. [Abstract] [Full-text]
29. Borderline epithelial tumors of the ovary.
    Mod Pathol, 18: S33-50. [Abstract] [Full-text]
30. Origins and molecular pathology of ovarian cancer.
    Mod Pathol, 18: S19-32. [Abstract] [Full-text]
31. A brief history of the pathology of the gonads.
    Mod Pathol, 18: S3-S17. [Abstract] [Full-text]
32. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.
    Mod Pathol, 18: S81-98. [Abstract] [Full-text]
33. Ovarian carcinomas, including secondary tumors: diagnostically challenging areas.
    Mod Pathol, 18: S99-111. [Abstract] [Full-text]
34. Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions.
    Mod Pathol, 18: S113-29. [Abstract] [Full-text]
35. Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: results of a prospective study.
    Radiother Oncol, 74(3): 267-74. [Abstract] [Full-text]
36. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
    J Biol Chem, 280(11): 10564-71. [Abstract] [Full-text]
37. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15.
    Mol Cancer Ther, 4(3): 487-93. [Abstract] [Full-text]
38. Association of dietary vitamin A, carotenoids, and other antioxidants with the risk of ovarian cancer.
    Cancer Epidemiol Biomarkers Prev, 14(3): 669-76. [Abstract] [Full-text]
39. An EGF receptor inhibitor induces RAR-beta expression in breast and ovarian cancer cells.
    Biochem Biophys Res Commun, 329(4): 1253-9. [Abstract] [Full-text]
40. Is family history related to preventive health behaviors and medical management in breast cancer patients?
    Breast Cancer Res Treat, 90(1): 47-54. [Abstract] [Full-text]
41. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Bioconjug Chem, 16(2): 354-60. [Abstract] [Full-text]
42. Cigarette smoking and the risk of ovarian cancer in the Japanese population: findings from the Japanese Collaborate Cohort study.
    J Obstet Gynaecol Res, 31(2): 144-51. [Abstract] [Full-text]
43. Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
    J Obstet Gynaecol Res, 31(2): 120-6. [Abstract] [Full-text]
44. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer.
    Cancer Sci, 96(3): 197-201. [Abstract] [Full-text]
45. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
    J Clin Oncol, 23(9): 1867-74. [Abstract] [Full-text]
46. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
    J Clin Oncol, 23(9): 1859-66. [Abstract] [Full-text]
47. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells.
    Naunyn Schmiedebergs Arch Pharmacol, 371(2): 141-51. [Abstract] [Full-text]
48. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression.
    J Biol Chem, 280(12): 11961-72. [Abstract] [Full-text]
49. Anti-tumor efficacy of the nucleoside analog 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl) cytosine (4'-thio-FAC) in human pancreatic and ovarian tumor xenograft models.
    Int J Cancer, 114(6): 1002-9. [Abstract] [Full-text]
50. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells.
    Cancer Res, 65(6): 2234-42. [Abstract] [Full-text]
51. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.
    Cancer Res, 65(6): 2162-9. [Abstract] [Full-text]
52. Cancer by negative heterosis: breast and ovarian cancer excess in hybrids of inbred ethnic groups.
    Med Hypotheses, 64(5): 1002-6. [Abstract] [Full-text]
53. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
    Ann Oncol, 16(4): 590-6. [Abstract] [Full-text]
54. Fertility-sparing surgery for malignancies in women.
    J Natl Cancer Inst Monogr. [Abstract] [Full-text]
55. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection.
    Br J Cancer, 92(6): 1026-32. [Abstract] [Full-text]
56. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.
    Br J Cancer, 92(6): 1019-25. [Abstract] [Full-text]
57. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells.
    Br J Cancer, 92(6): 1149-58. [Abstract] [Full-text]
58. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
    Carcinogenesis, 26(4): 855-63. [Abstract] [Full-text]
59. The effect of experiential knowledge on construction of risk perception in hereditary breast/ovarian cancer.
    J Genet Couns, 14(1): 55-69. [Abstract] [Full-text]
60. Introducing the MUC16 gene: implications for prevention and early detection in epithelial ovarian cancer.
    Biol Res Nurs, 6(4): 262-7. [Abstract] [Full-text]
61. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Clin Cancer Res, 11(6): 2408-15. [Abstract] [Full-text]
62. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival.
    Clin Cancer Res, 11(6): 2188-94. [Abstract] [Full-text]
63. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
    Clin Cancer Res, 11(6): 2149-55. [Abstract] [Full-text]
64. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Clin Cancer Res, 11(6): 2123-31. [Abstract] [Full-text]
65. Geranylgeranylacetone inhibits lysophosphatidic acid-induced invasion of human ovarian carcinoma cells in vitro.
    Cancer, 103(7): 1529-36. [Abstract] [Full-text]
66. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
    Cancer, 103(7): 1397-401. [Abstract] [Full-text]
67. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Cancer, 103(7): 1388-96. [Abstract] [Full-text]
68. Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases.
    Neurosurg Rev, 28(2): 120-3. [Abstract] [Full-text]
69. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Hum Pathol, 36(3): 242-9. [Abstract] [Full-text]
70. Ascites, pleural effusion, and CA 125 elevation in an SLE patient, either a Tjalma syndrome or, due to the migrated Filshie clips, a pseudo-Meigs syndrome.
    Gynecol Oncol, 97(1): 288-91. [Abstract] [Full-text]
71. Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii.
    Gynecol Oncol, 97(1): 282-4. [Abstract] [Full-text]
72. Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors.
    Gynecol Oncol, 97(1): 266-70. [Abstract] [Full-text]
73. Borderline endometrioid tumor arising in a paratubal cyst: a case report.
    Gynecol Oncol, 97(1): 263-5. [Abstract] [Full-text]
74. Steroid cell tumors, not otherwise specified (NOS), in an accessory ovary: a case report and literature review.
    Gynecol Oncol, 97(1): 260-2. [Abstract] [Full-text]
75. Primary ovarian large B-cell lymphoma in patient with juvenile rheumatoid arthritis treated with low dose Methotrexate.
    Gynecol Oncol, 97(1): 249-52. [Abstract] [Full-text]
76. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
    Gynecol Oncol, 97(1): 228-33. [Abstract] [Full-text]
77. A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
    Gynecol Oncol, 97(1): 223-7. [Abstract] [Full-text]
78. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
    Gynecol Oncol, 97(1): 200-5. [Abstract] [Full-text]
79. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
    Gynecol Oncol, 97(1): 195-9. [Abstract] [Full-text]
80. FDG-PET for management of cervical and ovarian cancer.
    Gynecol Oncol, 97(1): 183-91. [Abstract] [Full-text]
81. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma.
    Gynecol Oncol, 97(1): 178-82. [Abstract] [Full-text]
82. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level.
    Gynecol Oncol, 97(1): 155-65. [Abstract] [Full-text]
83. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
    Gynecol Oncol, 97(1): 110-7. [Abstract] [Full-text]
84. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study.
    Gynecol Oncol, 97(1): 104-9. [Abstract] [Full-text]
85. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Gynecol Oncol, 97(1): 84-9. [Abstract] [Full-text]
86. Histologic subtypes and laterality of primary epithelial ovarian tumors.
    Gynecol Oncol, 97(1): 80-3. [Abstract] [Full-text]
87. The role of secondary cytoreductive surgery for recurrent ovarian cancer.
    Gynecol Oncol, 97(1): 74-9. [Abstract] [Full-text]
88. Molecular cytogenetics of ovarian granulosa cell tumors by comparative genomic hybridization.
    Gynecol Oncol, 97(1): 68-73. [Abstract] [Full-text]
89. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
    Gynecol Oncol, 97(1): 60-7. [Abstract] [Full-text]
90. p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: a multivariate analysis.
    Gynecol Oncol, 97(1): 46-52. [Abstract] [Full-text]
91. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
    Gynecol Oncol, 97(1): 26-34. [Abstract] [Full-text]
92. Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas.
    Gynecol Oncol, 97(1): 16-25. [Abstract] [Full-text]
93. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol, 97(1): 10-5. [Abstract] [Full-text]
94. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Oncologist, 10(3): 205-14. [Abstract] [Full-text]
95. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.
    Mol Cell Proteomics, 4(4): 346-55. [Abstract] [Full-text]
96. Effects of progesterone on ovarian tumorigenesis in xenografted mice.
    Cancer Lett, 221(1): 49-53. [Abstract] [Full-text]
97. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
    Curr Biol, 15(6): 561-5. [Abstract] [Full-text]
98. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.
    Support Care Cancer, 13(4): 219-27. [Abstract] [Full-text]
99. Oncolysis of human ovarian cancers by echovirus type 1.
    Int J Cancer, 115(2): 320-8. [Abstract] [Full-text]
100. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.
     Int J Cancer, 115(2): 312-9. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.